6-\textit{O}-angeloylplenolin exerts neuroprotection against lipopolysaccharide-induced neuroinflammation in vitro and in vivo

Yi-le Zhou\textsuperscript{1,3}, Yong-ming Yan\textsuperscript{2}, Si-yi Li\textsuperscript{1}, Dan-hua He\textsuperscript{1}, Sha Xiong\textsuperscript{1}, Su-fen Wei\textsuperscript{1}, Wei Liu\textsuperscript{1}, Ling Hu\textsuperscript{3}, Qi Wang\textsuperscript{1}, Hua-feng Pan\textsuperscript{1}, Yong-xian Cheng\textsuperscript{2} and Yong-qiang Liu\textsuperscript{1}

Neuroinflammation is one of the critical events in neurodegenerative diseases, whereas microglia play an important role in the pathogenesis of neuroinflammation. In this study, we investigated the effects of a natural sesquiterpene lactone, 6-\textit{O}-angeloylplenolin (6-OAP), isolated from the traditional Chinese medicine \textit{Centipeda minima} (L.) A.Br., on neuroinflammation and the underlying mechanisms. We showed that treatment with lipopolysaccharide (LPS) caused activation of BV2 and primary microglial cells and development of neuroinflammation in vitro, evidenced by increased production of inflammatory cytokines TNF-\textit{α} and IL-1\textit{β}, the phosphorylation and nuclear translocation of NF-κ\textit{B}, and the transcriptional upregulation of COX-2 and iNOS, leading to increased production of proinflammatory factors NO and PGE\textsubscript{2}. Moreover, LPS treatment induced oxidative stress through increasing the expression levels of NOX2 and NOX4. Pretreatment with 6-OAP (0.5–4 \textmu M) dose-dependently attenuated LPS-induced NF-κ\textit{B} activation and oxidative stress, thus suppressed neuroinflammation in the cells. In a mouse model of LPS-induced neuroinflammation, 6-OAP (5–20 mg·kg\textsuperscript{-1}·d\textsuperscript{-1}, ip, for 7 days before LPS injection) dose-dependently inhibited the production of inflammatory cytokines, the activation of the NF-κ\textit{B} signaling pathway, and the expression of inflammatory enzymes in brain tissues. 6-OAP pretreatment significantly ameliorated the activation of microglia and astrocytes in the brains. 6-OAP at a high dose caused a much stronger antineuroinflammatory effect than dexamethansone (DEX). Furthermore, we demonstrated that 6-OAP pretreatment could inhibit LPS-induced neurite and synaptic loss in vitro and in vivo. In conclusion, our results demonstrate that 6-OAP exerts antineuroinflammatory effects and can be considered a novel drug candidate for the treatment of neuroinflammatory diseases.

**Keywords:** 6-\textit{O}-angeloylplenolin; Traditional Chinese medicine; LPS; neuroinflammation; microglia; NF-κ\textit{B}; oxidative stress; dexamethansone

**Acta Pharmacologica Sinica** (2020) 41:10–21; https://doi.org/10.1038/s41401-019-0261-5

**INTRODUCTION**

In the central nervous system (CNS), neuroinflammation is regarded as one of the critical events in neurodegenerative diseases [1], including Parkinson’s disease, Alzheimer’s disease, prion diseases, and multiple sclerosis [2–5]. Microglia, as the main immunoeffector cells in the CNS, play a critical role in the occurrence and development of neuroinflammation [3, 6]. By sensing inflammatory stimuli, microglia can be activated, and morphological changes and the production of inflammatory cytokines, chemokines, and reactive oxygen species (ROS) [7–9], which further induce the activation of astrocytes and cause neuroinflammatory damage [10–12], can occur. Thus, the suppression of microglial activation has been recognized as an attractive option for the alleviation of neuroinflammation-related diseases.

Multiple signaling pathways have been reported to mediate inflammatory progression in the CNS, and the NF-κ\textit{B} signaling pathway is best characterized in the development of neuroinflammation. LPS, as the polysaccharide component of gram-negative bacteria, can bind to toll-like receptor 4 and activate the NF-κ\textit{B} signal pathway [13, 14], and it is most frequently used to investigate the inflammatory responses of microglia. Under normal conditions, IkB family members, such as IkB-\textit{α} and IkB-\textit{β}, bind to NF-κ\textit{B} and sequester it in the cytoplasm. In response to inflammatory stimulation, IkB family members can be phosphorylated and degraded; then NF-κ\textit{B} is activated and allowed to enter the nucleus [15]. Activated NF-κ\textit{B} induces the expression of inflammatory cytokines, such as IL-1\textit{β} and TNF-\textit{α}; the inflammatory enzymes iNOS and COX-2 are also regulated by NF-κ\textit{B} and mediate the production of the proinflammatory factors NO and PGE\textsubscript{2}, which potentiate the pathogenesis of neuroinflammation [16, 17]. Moreover, inflammation-mediated oxidative stress can further promote the development of neuroinflammation [18, 19]. Numerous studies have demonstrated that NOX protein family members, such as NOX2 and NOX4, can induce ROS.
production in activated microglial cells and facilitate the activation of NF-κB [20–23]; meanwhile, NF-κB also exerts positive feedback to regulate the expression of NOX2 and NOX4, which comprehensively induces ROS production [24–26]. As stated above, NF-κB plays a key role in the development of neuroinflammation, which has been widely accepted as a promising therapeutic target for the treatment of neuroinflammatory diseases.

Numerous natural products exert anti-inflammatory activities and have attracted great attention as alternative therapeutic agents against neuroinflammatory diseases [27–29]. *C. minima* is a traditional Chinese medicine that has antibacterial and antimarial activities [30, 31] and is effective in the treatment of a number of inflammatory diseases, such as arthritis, rhinitis, sinusitis, and diarrhea [32–34]. Furthermore, multiple components, including sesquiterpene lactones, flavonoids, and terpenes, have been purified from *C. minima* [35–38]; however, the active compounds that have anti-inflammatory activity remain unknown. Previously, 6-OAP was identified as one of the most abundant sesquiterpene lactones isolated from *C. minima* [39]. 6-OAP has multiple biological activities, including antibacterial, antiprotozoal, and anticancer activities [40–42]. Moreover, 6-OAP has a favorable pharmacokinetic profile and high bioavailability, and no obvious acute toxicity is observed in mice treated with a high dose of 6-OAP [41], suggesting that 6-OAP is a safe agent; thus, the therapeutic potential of 6-OAP in anti-inflammatory diseases is worth further investigation.

In this study, we examined the effect and underlying mechanism of 6-OAP in neuroinflammation and assessed its therapeutic potential in LPS-induced neuroinflammatory models both in vitro and in vivo. Our results first demonstrate that 6-OAP exhibits neuroprotective effects via the amelioration of neuroinflammation, suggesting that the natural compound 6-OAP has therapeutic potential in neuroinflammatory diseases.

**MATERIALS AND METHODS**

Reagents and antibodies

6-OAP was extracted from *C. minima* as described, and the purity was as high as 98% [39]. 6-OAP was dissolved in DMSO at a concentration of 20 mM to produce a stock solution. LPS from *Escherichia coli* 055:B5 was purchased from Sigma (St. Louis, MO, USA). Hoechst 33342, 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) and DAPI were obtained from Beyotime Institute of Biotechnology (Shanghai, China). Celecoxib and DEX were purchased from MCE (Medchem Express, NJ, USA). Antibodies against iNOS, NOX2, NOX4, COX-2, and lamin B1 were obtained from Abcam (Cambridge, MA, USA). Antibodies against IκB-α, phospho-IκB-α, NF-κB p65, phospho-NF-κB p65, synaptophysin (SYN), NeuN, and β-actin were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies against Iba1, GFAP, and TNF-α were obtained from Millipore (Bedford, MA, USA). All secondary antibodies (horseradish peroxidase conjugated anti-rabbit IgG and anti-mouse IgG, Alexa Fluor 594-conjugated goat anti-rabbit IgG and FITC-conjugated goat anti-mouse IgG) were purchased from Cell Signaling Technology.

Cell culture and treatment

The murine microglial BV2 cell line (passage 4) was purchased from the Interlab Cell Line Collection (Leica, Wetzlar, Germany). The total neurite length was determined using NeuronJ [45]. Four random microscope fields per condition were quantified, and the ratio between the total neurite length and the number of neurons was used to calculate the average neurite length.

**Animals**

All experiments in this study were approved by and in accordance with the guidelines of the Animal Ethics Committee of Guangzhou University of Chinese Medicine. Six-week-old male C57BL/6J mice were purchased from Vital River Laboratory Animal Technology (Beijing, China). All mice were kept at 23 ± 1 °C under a 12 h light/dark cycle and had access to water and food ad libitum for at least 1 week before the experiment. The mice were randomly divided into six groups (n = 12 per group): vehicle control (5% cremophor + 0.05% ethanol in normal saline), LPS (1 mg/mL), LPS + 6-OAP (5, 10, 20 mg/kg) and LPS + DEX (1 mg/kg). DEX was used as an anti-inflammatory positive control. Intraperitoneal (i.p.) injections of 6-OAP and DEX were administered for 7 consecutive days prior to a single i.p. injection of LPS, while the control group received an equal volume of saline. The mice were sacrificed 1 day after LPS administration, and the brain tissues were collected for subsequent experiments.

**Cell viability assay**

A 3-(4,5-dimethyl thiazol-2-yl)–2,5-diphenyl tetrazolium bromide (MTT) assay was used to detect cell viability in 96-well plates. Cells (1 × 10⁴) were plated in each well and treated with LPS for 24 h with or without 6-OAP, 10 μL of MTT working solution containing 5 mg/mL MTT was added to each well and the plates were incubated for 4 h at 37 °C. Then, the supernatant was removed, and the formazan crystal products were dissolved in 150 μL DMSO. The absorbance at 490 nm was detected, and the results were expressed as the mean percentage of absorbance in the treated versus control cells.

**Nitrite oxide (NO) assay**

NO production was detected by a Griess kit (Beyotime Institute of Biotechnology). In short, the cell supernatants were collected and centrifuged at 1000 r/min after 24 h treatment with LPS in the...
presence or absence of 6-OAP. Fifty microliters of each cell supernatant were collected, equal volumes of Griess reagent I and II working solutions were added, and the absorbance at a wavelength of 540 nm was measured within 10 min using a microplate reader. Sodium nitrite was used as a standard in the assay.

Fig. 1  6-OAP inhibits the activation of microglial cells. a Chemical structure of 6-OAP. b, c The percentage of cell viability for 24 h in BV2 cells was determined by a MTT assay. d, e The relative mRNA levels of TNF-α and IL-1β in BV2 cells were detected by real-time PCR analysis. f–i The production of TNF-α and IL-1β in BV2 (f, g) and primary microglial cells (h, i) were examined by ELISA. j Primary microglia was stained using Iba1 antibody (green) and DAPI (blue), purity of primary microglia can reach 95%. k Morphological changes of primary microglial cells (upper panel) and BV2 cells (lower panel) were observed under bright field of microscope, and representative pictures have been shown for comparison. Scale bar, 20 µm. All data are presented as the means ± SEM from three separate experiments. ##P < 0.01, ###P < 0.001 versus control cells. *P < 0.05, **P < 0.01, ***P < 0.001 versus LPS alone
ELISA for TNF-α, IL-1β, and PGE₂.

The concentrations of TNF-α and IL-1β were examined by using mouse TNF-α and IL-1β ELISA (Neobioscience Technology Co., Ltd., China), and PGE₂ was quantified using a competitive ELISA (Cusabio Biotech, China). Briefly, BV2 and primary microglial cells were stimulated with LPS (1 μg/ml) with or without 6-OAP, and the supernatants were collected and centrifuged after 8 h of treatment for TNF-α and IL-1β detection and after 24 h of treatment for PGE₂ detection. For the in vivo test, brain tissues were homogenized with cold PBS and centrifuged, and the supernatants were collected for the detection of TNF-α and IL-1β. The absorbance was read at a wavelength/reference wavelength of 450/650 nm on a microplate reader, according to the manufacturer’s instructions. The concentrations of TNF-α, IL-1β, and PGE₂ were calculated according to the standard curve and are presented as pg/mL.

Extracting cytoplasmic and nuclear proteins

BV2 cells and primary microglial cells were pretreated with the indicated concentrations of 6-OAP for 2 h and then stimulated with LPS (1 μg/ml) for 1 h. The cultured cells were harvested and washed twice with cold phosphate-buffered saline (PBS) after LPS stimulation. The cytoplasmic and nuclear protein fractions were extracted using a Nuclear and Cytoplasmic Extraction Kit (Beyotime Institute of Biotechnology) according to the manufacturer’s protocol.

Western blotting

At the end of LPS treatment, the cells and tissues were harvested and lysed using RIPA lysis buffer. After the quantification of the protein samples using a BCA Protein Assay Kit (Beyotime Institute of Biotechnology), equal amounts of protein per sample were loaded in each lane, separated by 10% SDS-PAGE, and transferred to PVDF membranes. The membranes were blocked with 5% skim milk for 2 h at room temperature and incubated with the indicated antibodies overnight at 4 °C. The PVDF membranes were further incubated with HRP-conjugated secondary antibodies for 2 h at room temperature. The protein bands were visualized using Immobilon Western HRP Substrate Luminol and mounted with Fluoromount G. Images were acquired using a confocal laser scanning microscope (Leica) or Leica fluorescence microscope. To count the cells for each condition of the animal experiments, six coronal sections from different levels across the anteroposterior axis of the hippocampus were chosen for immunostaining, and at least five images (picture size: 622.18 μm × 466.55 μm) were taken from the hippocampus, including the CA1 and dentate gyrus regions, of each brain section (Supplementary Fig. 2). The cells were counted semiautomatically using the ‘Analyze Particles’ function in ImageJ. In brief, the fluorescent images were converted to black and white following background subtraction, and the threshold was set at a level of 50 out of 255. Then, the cell size was set as ‘150-infinity’ to include nearly all cell particles using the ‘Analyze Particles’ function in ImageJ. The parameters were kept identical for all images to maintain consistency.

Statistical analysis

All quantitative measures are presented as the mean ± standard error of the mean. An unpaired t test was performed to compare two samples to determine the statistical significance of the difference. P < 0.05 was considered statistically significant. Data handling and statistical processing were performed using GraphPad Prism 7.0 (GraphPad Software, San Diego, CA, USA). All experiments were performed at least three times.

RESULTS

6-OAP inhibits the LPS-induced production of inflammatory mediators in microglial cells

To determine the antineuroinflammatory activity of 6-OAP (Fig. 1a), we first examined the drug toxicity of 6-OAP in BV2 microglial cells. As shown in Fig. 1b, c, 6-OAP at the indicated concentrations with or without LPS treatment did not affect the viability of BV2 cells, thus excluding the possibility of toxic effects of 6-OAP. Subsequently, we examined the inhibitory effects of 6-OAP on the activation of microglial cells. Upon LPS stimulation, the mRNA levels of the proinflammatory cytokines TNF-α and IL-1β were significantly increased, whereas 6-OAP treatment significantly inhibited the LPS-induced upregulation of proinflammatory cytokines in BV2 cells, as determined by real-time PCR analysis (Fig. 1d, e). Consistently, ELISA also confirmed that 6-OAP was able to inhibit the production of TNF-α and IL-1β induced by LPS in BV2 (Fig. 1f, g) and primary microglial cells (Fig. 1h, i). Studies have reported that the activation of microglia can be reflected by morphological changes [46], and we observed that rod-shaped primary microglia were markedly transformed into amoeboid microglia after 24 h of LPS treatment (Fig. 1j, k); consequently, the immunofluorescence staining

For the in vivo experiments, mice were perfused with PBS followed by 4% paraformaldehyde (PFA). The brains were removed and fixed overnight in 4% PFA, cryoprotected with 30% sucrose in PBS, and frozen in Tissue Tek-OCT (Sakura Finetek, CA, USA). Coronal sections (12 μm) were prepared using a Leica CM 3000 cryostat. For the in vitro experiments, BV2 and primary microglial cells were pretreated with the indicated concentrations of 6-OAP for 2 h and then stimulated with LPS (1 μg/ml) for an additional 1 h. The immunofluorescence staining of sections and cultured cells was carried out according to standard protocols. Briefly, the sections or cells were fixed with 4% PFA for 15 min, blocked and permeabilized with PBST (PBS with 0.1% Triton X-100) containing 10% normal goat serum for 60 min at room temperature, incubated with the indicated primary antibody (1:500) at 4 °C overnight, and stained with the corresponding secondary antibody (Alexa Fluor 594 goat anti-rabbit IgG or FITC goat anti-mouse IgG, 1:500) for 2 h at room temperature. The sections or cells were counterstained with DAPI or Hoechst 33342 and mounted with Fluoromount G. Images were acquired using a confocal laser scanning microscope (Leica) or Leica fluorescence microscope. To count the cells for each condition of the animal experiments, six coronal sections from different levels across the anteroposterior axis of the hippocampus were chosen for immunostaining, and at least five images (picture size: 622.18 μm × 466.55 μm) were taken from the hippocampus, including the CA1 and dentate gyrus regions, of each brain section (Supplementary Fig. 2). The cells were counted semiautomatically using the ‘Analyze Particles’ function in ImageJ. In brief, the fluorescent images were converted to black and white following background subtraction, and the threshold was set at a level of 50 out of 255. Then, the cell size was set as ‘150-infinity’ to include nearly all cell particles using the ‘Analyze Particles’ function in ImageJ. The parameters were kept identical for all images to maintain consistency.

Statistical analysis

All quantitative measures are presented as the mean ± standard error of the mean. An unpaired t test was performed to compare two samples to determine the statistical significance of the difference. P < 0.05 was considered statistically significant. Data handling and statistical processing were performed using GraphPad Prism 7.0 (GraphPad Software, San Diego, CA, USA). All experiments were performed at least three times.
morphology of BV2 cells was converted from a bipolar to an amoeboid shape, and the cell bodies were enlarged after LPS stimulation (Fig. 1k); furthering demonstrating that BV2 cells were markedly activated by inflammatory stimulation. However, 6-OAP treatment obviously reversed the morphological changes caused by LPS (Fig. 1k). The results above suggest that 6-OAP exerts antineuroinflammatory effects via the attenuation of microglial cell activation.

Fig. 2 6-OAP show inhibitory effects on NF-κB signaling pathway. a–d The protein levels of NF-κB p65, phospho-NF-κB p65, IκB-α, and phospho-IκB-α were analyzed by Western blotting. β-actin was used as a loading control. e, f The nuclear part of NF-κB was detected by western blotting. lamin B1 was used as a loading control. g Nuclear localization of NF-κB of primary microglial cells (upper panel) and BV2 cells (lower panel) was determined by immunostaining with NF-κB subunit p65 (red), and counterstained with Hoechst 33342 (blue), the images were obtained by confocal microscopy. h The percentage of nuclear NF-κB-positive cells among cultured microglial cells was quantified. Scale bar, 20 µm. Relative protein levels were quantified by densitometry analysis using ImageJ software. Data are presented as the means ± SEM from three separate experiments. **P < 0.01, ***P < 0.001 versus control cells. *P < 0.05, **P < 0.01, ***P < 0.001 versus LPS alone. p-NF-κB: phospho-NF-κB p65, p-IκB-α: phosphor-IκB-α. PC: primary microglial cells.
6-OAP exhibits antineuroinflammatory effects through inhibiting the NF-κB signaling pathway. NF-κB plays a key role in the transcriptional regulation of inflammatory cytokines and the development of inflammation. Thus, we examined whether 6-OAP can inhibit neuroinflammation by regulating NF-κB activity in microglial cells. As shown in Fig. 2a, LPS stimulation increased the phosphorylation of NF-κB rapidly within 30 min, while IkB-α was phosphorylated and degraded. However, 6-OAP treatment significantly inhibited the phosphorylation of NF-κB and reversed the phosphorylation and downregulation of IkB-α induced by LPS in BV2 and primary microglial cells (Fig. 2a-d). Activated NF-κB can enter the nucleus and initiate transcription. Thus, we examined the effect of 6-OAP on the nuclear translocation of NF-κB induced by LPS. Upon LPS stimulation for 1 h, nuclear NF-κB increased obviously in BV2 and primary microglial cells, as determined by Western

Fig. 3 6-OAP suppresses the LPS-induced expression of iNOS and COX-2. a-c The protein levels of iNOS and COX-2 in BV2 and primary microglial cells after 24 h treatment were analyzed by Western blotting. β-actin was used as an internal control. d, e The relative mRNA levels of iNOS and COX-2 in BV2 cells were detected by real-time PCR analysis. f–i Culture supernatants of BV2 and primary microglial cells were harvested after 24 h treatment, the concentration of Nitrite oxide (f, g) and PGE2 (h, i) were determined and quantified using the Griess reagent and competitive ELISA, respectively. Celecoxib was used as a positive control for COX-2 inhibition. Relative protein levels were quantified by densitometry analysis using ImageJ software. The quantification from three independent experiments was analyzed and expressed as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 versus LPS group. PC: primary microglial cells.

Acta Pharmacologica Sinica (2020) 41:10 – 21
6-OAP suppresses iNOS and COX-2 expression induced by LPS in microglial cells

Inflammatory enzymes, such as iNOS and COX-2, can be upregulated by activated NF-κB and augment the inflammatory response through the production of NO and PGE₂. Thus, we examined the effect of 6-OAP on iNOS and COX-2 expression. As shown in Fig. 3a, LPS treatment markedly increased the protein levels of iNOS and COX-2 in BV2 and primary microglial cells, and the effects were attenuated by 6-OAP (Fig. 3a–c). Furthermore, we found that 6-OAP decreased the mRNA levels of iNOS and COX-2 induced by LPS in BV2 cells (Fig. 3d–e), indicating that 6-OAP regulates the expression of iNOS and COX-2 at the transcriptional level. Consistently, 6-OAP treatment significantly suppressed the production of NO (Fig. 3f, g) and PGE₂ (Fig. 3h, i) induced by LPS in BV2 and primary microglial cells, demonstrating that 6-OAP exerts inhibitory effects on the expression of inflammatory enzymes and the secretion of inflammatory mediators.

6-OAP ameliorates inflammation-induced oxidative stress through decreasing the expression of NOX proteins

Neuroinflammation is frequently accompanied by the increased production of superoxide and ROS [21], and NOX protein family members, such as NOX-2 and NOX-4, can produce high levels of ROS in response to brain injury and inflammation [10]. Thus, we further examined whether 6-OAP regulates inflammation-related ROS production. We found that high expression levels of NOX-2 and NOX-4 were induced by LPS in BV2 and primary microglial cells (Fig. 4a, b); consistently, elevated intracellular ROS production was observed in BV2 cells (Fig. 4c, d). However, when BV2 and primary microglial cells were pretreated with 6-OAP, the induction of NOX-2 and NOX-4 by LPS was markedly attenuated (Fig. 4a, b); meanwhile, LPS-induced ROS production was decreased in BV2 cells (Fig. 4c, d). The results demonstrate that 6-OAP has a potential role in ameliorating neuroinflammation-induced oxidative stress.

6-OAP protects neurons from microglia-mediated inflammatory injury

The production of proinflammatory mediators and ROS induced by LPS in microglia can potentially cause neuronal damage [9, 10]. Thus, we tested the neuroprotective effects of 6-OAP against microglia-mediated inflammatory injury. First, we detected the toxicity of 6-OAP in HT22 hippocampal neuronal cells and found that 6-OAP did not show any cytotoxicity based on a cell viability assay (Fig. 5a), indicating that 6-OAP at the tested concentrations is nontoxic to HT22 cells. For cocultures of microglial cells and
neurons, conditioned medium harvested from BV2 cells was used to culture HT22 cells. As expected, the LPS-conditioned medium (LPS-CM) from the BV2 cells significantly decreased the cell viability of the HT22 cells within 24 h, whereas the conditioned medium harvested from the BV2 cells that were cotreated with LPS and 6-OAP (6-OAP-CM) was less cytotoxic than the LPS-CM (Fig. 5b). However, LPS-CM induced the neuronal shrinkage of the HT22 cells (Fig. 5c), but not cell death, as evaluated by nuclear fragmentation and condensation (Supplementary Fig. 1). The morphology of the HT22 cells was obviously improved by 6-OAP pretreatment (Fig. 5c). Studies have demonstrated that neurotoxic insult can frequently induce neurite loss that is characteristic of the early stages of neurodegeneration [47]. Thus, to determine whether inflammatory injury causes neurite breakdown, primary cortical neurons were further used for coculture experiments. We found that the proinflammatory mediators produced by BV2 cells significantly diminished the neurite length of neurons and that the effect was attenuated by 6-OAP pretreatment (Fig. 5c, d), suggesting that 6-OAP can maintain neuronal integrity and protect neurons from microglia-mediated inflammatory injury through attenuating the production of toxic proinflammatory mediators.

6-OAP suppresses the inflammatory response in an LPS-challenged mouse model
As stated above, 6-OAP can significantly inhibit the development of neuroinflammation in microglial cells. We further assessed the therapeutic potential of 6-OAP in a mouse model of neuroinflammation induced by LPS. The intraperitoneal injection of LPS for 1 day significantly induced the expression and secretion of TNF-α and IL-1β (Fig. 6a, b). Meanwhile, LPS also induced the phosphorylation of NF-κB, promoted the phosphorylation and subsequent degradation of IκB-α, and upregulated the expression levels of iNOS and COX-2 in hippocampal tissue (Fig. 6c), suggesting that neuroinflammation was markedly induced after 1 day of LPS treatment. However, 6-OAP administration significantly attenuated the LPS-induced production of TNF-α and IL-1β, as detected by real-time PCR (Fig. 6a) and ELISA (Fig. 6b), and inhibited the induction of iNOS and COX-2 (Fig. 6c–e). Moreover, 6-OAP treatment reduced the LPS-induced phosphorylation of NF-κB and IκB-α and reversed the expression level of IκB-α in hippocampal tissue (Fig. 6c, f–h). These results suggest that 6-OAP has a potential role in the amelioration of LPS-induced neuroinflammation, and 6-OAP at a high dose exhibited a much stronger antineuroinflammatory effect than DEX.

6-OAP inhibits LPS-induced microglial and astrocyte activation in the LPS-treated mouse brain
Microglial and astrocyte activation are key events that contribute to the development of neuroinflammation and lead to the production of multiple proinflammatory mediators that aggravate neuronal damage. The hippocampus is the most vulnerable region in the brain and can be easily affected by inflammatory mediators. To examine the antineuroinflammatory and neuroprotective effects of 6-OAP, we injected the vehicle or 6-OAP for 3 days before LPS treatment. The results showed that 6-OAP significantly reduced the LPS-induced expression of proinflammatory cytokines TNF-α and IL-1β, as detected by real-time PCR and ELISA (Fig. 6a,b). Moreover, 6-OAP also inhibited the LPS-induced expression of iNOS and COX-2 in hippocampal tissue (Fig. 6c–e). These results suggest that 6-OAP has a potential role in the amelioration of LPS-induced neuroinflammation, and 6-OAP at a high dose exhibited a much stronger antineuroinflammatory effect than DEX.
effects of 6-OAP, immunostaining was performed with antibodies against Iba1 and GFAP, specific markers of microglia and astrocytes, respectively. We found that LPS treatment for 1 day obviously increased the number of Iba1- and GFAP-positive cells in the hippocampus (Supplementary Fig. 2a–c), suggesting that microglia and astrocytes were highly activated in the brain tissue, which is consistent with the increased expression of GFAP and Iba1 in hippocampal tissue detected by Western blotting (Fig. 7d, e). Both 6-OAP and DEX treatment markedly reduced the number of microglial cells and astrocytes (Supplementary Fig. 2a–c) and decreased the expression of Iba1 and GFAP in the hippocampus (Fig. 7d, e) compared with that in the LPS-treated group. In line with these results, LPS treatment for 1 day increased the expression of GFAP and Iba1 in hippocampal tissue detected by Western blotting (Fig. 7d, e).
with this, 6-OAP treatment also attenuated the LPS-induced activation of microglial cells in the cortex (Supplementary Fig. 2d). Then, we examined whether 6-OAP exerts antineuroinflammatory effects via the specific inhibition of microglial and astrocyte activation. We found that LPS markedly induced TNF-α production in microglial cells and astrocytes in the hippocampal dentate gyrus (DG) region (Fig. 7a–c) but had no effect on hippocampal neurons (Supplementary Fig. 3), suggesting that activated microglia and astrocytes contribute to the production of proinflammatory factors and the development of neuroinflammation; however, 6-OAP treatment markedly attenuated the production of TNF-α in microglia and astrocytes (Fig. 7a–c). Moreover, to demonstrate the neuroprotective effects of 6-OAP, the synaptic vesicle membrane protein SYN was examined by Western blotting. 6-OAP administration markedly attenuated the LPS-induced reduction in SYN, as detected by Western blotting (Fig. 7d, e).

The results demonstrate that 6-OAP exerts antineuroinflammatory and neuroprotective effects through inhibiting the activation of microglia and astrocytes.

**DISCUSSION**

*C. minima*, as a traditional Chinese medicinal herb, has been demonstrated to elicit anti-inflammatory, antioxidative, and antitumor activity [32]. Several sesquiterpene lactones that exert multiple biological activities have been isolated from *C. minima* [38, 48–50]. In this study, we examined whether 6-OAP acts as a potential anti-inflammatory compound in *C. minima* and found that 6-OAP can significantly inhibit the activation of the NF-κB signaling pathway and decrease the expression levels of

---

**Fig. 7** 6-OAP inhibits the activation of microglia and astrocyte in LPS-treated mouse brain. a, b Coronal sections of mouse brain were incubated with the primary antibody against Iba1 (green) and TNF-α (red) (a) or GFAP (green) and TNF-α (red) (b) in the hippocampal DG region. DAPI was used to counter stain cell nuclei. Scale bar, 20 µm. c Bar graphs representing the quantification of the average cell number per field of TNF-α-positive microglia and astrocyte in the DG region of hippocampus. d The protein levels of SYN, Iba1, and GFAP in the hippocampal tissues were detected by Western blotting. e The densitometry of indicated immunoblot bands was determined by ImageJ software. All data were expressed as the means ± SEM from five mice of each group. **p < 0.01, ***p < 0.001 versus control group. *p < 0.05, **p < 0.01 versus LPS treated group.
inflammatory cytokines and enzymes. Furthermore, 6-OAP exerts antineuroinflammatory effects in an LPS-treated mouse model, demonstrating that 6-OAP has potential anti-inflammatory activity. Our previous results demonstrated that 6-OAP exhibits inhibitory effects on tumor cell proliferation. Here, we found that 6-OAP does not affect the cell viability of microglia at the tested concentrations, indicating that 6-OAP can selectively inhibit tumor cell growth and spare normal cells. These results are consistent with our previous results that 6-OAP administration has no apparent acute toxicity in vivo [42], further supporting the safety of the agent.

The potential contribution of inflammation to the progression of neurodegenerative diseases has significantly prompted the consideration of anti-inflammatory treatment strategies. Nonsteroidal anti-inflammatory drugs and the corticosteroid DEX are commonly prescribed to treat inflammatory diseases, and these drugs appear to decrease the incidence of neurodegenerative diseases [51]. However, clinical trials of anti-inflammatory therapies have yielded relatively modest benefits [52], and these drugs have been shown to produce diverse side effects. For example, DEX, which is widely used to treat inflammatory diseases, has been shown to exhibit immunosuppressive properties and induce side effects after long-term administration [53, 54]. Recently, numerous natural products from herbal plants, such as ginsengsides and curcumin, have been reported to exert neuroprotection against inflammation and oxidative stress with fewer side effects and to exhibit promising therapeutic potential for the treatment of neuroinflammatory and neurodegenerative diseases [55]. Here, we demonstrated that the natural compound 6-OAP exerts neuroprotection via the amelioration of neuroinflammation both in vitro and in vivo. 6-OAP was shown to exhibit multiple biological activities, including the attenuation of the LPS-induced activation of COX-2, iNOS, and the NF-κB signaling pathway and the alleviation of oxidative stress through the decrease of NOX proteins. Moreover, the administration of 6-OAP at a high dose possessed a better therapeutic potential than DEX in an LPS-induced mouse model of neuroinflammation. Thus, the clinical development of natural products for neuroinflammatory diseases needs further consideration.

NF-κB plays a pivotal role in the development of inflammation, and NF-κB can regulate the expression of multiple proinflammatory factors and enzymes [16]. In this study, we also demonstrated that 6-OAP can significantly inhibit the LPS-induced activation of NF-κB and decrease the expression of inflammatory cytokines, COX-2, and iNOS. A previous study also found that 6-OAP can inhibit the TNF-α-induced activation of NF-κB [41], suggesting that NF-κB plays an important role in the mediation of the anti-inflammatory effects of 6-OAP. However, it is possible that 6-OAP can antagonize many steps in the NF-κB inflammatory cascade, and the identification of the targets of 6-OAP is worth further investigation.

Inflammation can induce the generation of oxidative stress and vice versa. Existing evidence has demonstrated that NOX family members can mediate ROS generation, and NOX-2 and NOX-4 have been reported to be mainly responsible for oxidative stress induction in the CNS [26]. In our study, we also found that LPS can markedly increase the expression levels of NOX-2 and NOX-4 and induce ROS production in microglial cells, indicating that NOX protein family members mediate LPS-induced ROS generation. However, 6-OAP administration was shown to decrease the expression levels of NOX-2 and NOX-4 and reduce ROS production in microglial cells, suggesting that 6-OAP can suppress ROS generation by decreasing the expression of NOX proteins in the CNS and that this effect can attenuate the development of neuroinflammatory diseases.

Both microglial cells and astrocytes are widely accepted to contribute to the development of neuroinflammation. Microglial cells, which recruit astrocytes by secreting cytokines and acute-phase proteins, are normally the first cells to be activated in response to injury and infection. It has been reported that LPS treatment can induce the development of neuroinflammation within 24 h via the activation of microglial cells and astrocytes [56]. In line with previous reports, our study also found that a single dose of LPS can induce a neuroinflammatory response, characterized by the accumulation of activated microglial cells and astrocytes in the hippocampus and cortex, in mice. 6-OAP administration can markedly attenuate the LPS-induced activation of microglia and astrocytes and decrease the generation of inflammatory cytokines and enzymes. Furthermore, studies have reported that sustained LPS treatment induces amyloidogenesis and astrogliosis, which result in neuronal damage and memory dysfunction, and acute LPS administration can potently induce synaptic damage [57, 58]. Our study demonstrated that the proinflammatory mediators produced by activated microglial cells can significantly induce neurite and synaptic loss both in vitro and in vivo, and we did not observe obvious apoptotic cell death after short-term inflammatory stimulation, indicating that 6-OAP treatment can potentially protect neurons from inflammatory injury.

In conclusion, we have demonstrated that 6-OAP exerts antineuroinflammatory and neuroprotective effects through inhibiting the production of proinflammatory factors and attenuating the activation of inflammatory enzymes and NF-κB signaling both in vitro and in vivo, suggesting that 6-OAP has promising therapeutic potential for neuroinflammatory diseases.

ACKNOWLEDGEMENTS

This work was supported by Guangzhou Science Technology and Innovation Commission Technology Research Projects (201805010005), the National Natural Science Foundation of China (81473740, 81673627, 81673946, 81802776), the National Science Fund for Distinguished Young Scholars (81525026), and the National Key Research and Development Program of China “Research and Development of Comprehensive Technologies on Chemical Fertilizer and Pesticide Reduction and Synergism” (2017YFD0201402).

AUTHOR CONTRIBUTIONS

YLZ, YMY, HFP, YXC and YQL designed the experiments, collected and analyzed the data, and drafted the paper. YLZ, SYL and DHH performed the molecular experiments, and YLZ, SX, SFW, WL and YQL participated in animal surgery and data collection. YLZ, QW, LH, HFP, YXC and YQL revised the paper. All authors have read and approved the final submitted paper.

ADDITIONAL INFORMATION

The online version of this article (https://doi.org/10.1038/s41401-019-0261-5) contains supplementary material, which is available to authorized users.

Competing interests: The authors declare no competing interests.

REFERENCES

1. Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology. 2010;129:154–69.
2. Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJ, Rozemuller JM, Veerhuis R, Williams A. Neuroinflammation in Alzheimer's disease and prion disease. Glia. 2002;40:323–39.
3. Kim YS, Joh TH. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med. 2006;38:333–47.
4. McGeer EG, McGeer PL. Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:741–49.
5. Sanders P, De Keyser J. Janus faces of microglia in multiple sclerosis. Brain Res Rev. 2007;54:274–85.
6. Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmocol Exp Ther. 2003;304:1–7.
7. Al-Amin MM, Reza HM. Neuroinflammation: contemporary anti-inflammatory treatment approaches. Neurosci (Riyadh). 2014;19:87–92.
